Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.

Eli Lilly will report earnings on October 29, with the potential of Retatrutide as a future growth driver being a key focus.

Retatrutide is expected to be a significant growth driver for Eli Lilly, potentially surpassing Zepbound.